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Abstract
Background: Formulation and evaluation of public health policy commonly employs science-based mathematical
models. For instance, epidemiological dynamics of TB is dominated, in general, by ﬂow between actively and latently
infected populations. Thus modelling is central in planning public health intervention. However, models are highly
uncertain because they are based on observations that are geographically and temporally distinct from the
population to which they are applied.
Aims: We aim to demonstrate the advantages of info-gap theory, a non-probabilistic approach to severe uncertainty
when worst cases cannot be reliably identiﬁed and probability distributions are unreliable or unavailable. Info-gap is
applied here to mathematical modelling of epidemics and analysis of public health decision-making.
Methods: Applying info-gap robustness analysis to tuberculosis/HIV (TB/HIV) epidemics, we illustrate the critical role
of incorporating uncertainty in formulating recommendations for interventions. Robustness is assessed as the
magnitude of uncertainty that can be tolerated by a given intervention. We illustrate the methodology by exploring
interventions that alter the rates of diagnosis, cure, relapse and HIV infection.
Results: We demonstrate several policy implications. Equivalence among alternative rates of diagnosis and relapse
are identiﬁed. The impact of initial TB and HIV prevalence on the robustness to uncertainty is quantiﬁed. In some
conﬁgurations, increased aggressiveness of intervention improves the predicted outcome but also reduces the
robustness to uncertainty. Similarly, predicted outcomes may be better at larger target times, but may also be more
vulnerable to model error.
Conclusions: The info-gap framework is useful for managing model uncertainty and is attractive when uncertainties
on model parameters are extreme. When a public health model underlies guidelines, info-gap decision theory
provides valuable insight into the conﬁdence of achieving agreed-upon goals.
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Background
Public health policies aﬀect millions of people and deter-
mine the allocation of health care funds. However, select-
ing an intervention for a given population at a given time
is highly uncertain. Data supporting public health deci-
sions are scarce, of poor quality, not fully generalizable
and lack appropriate controls [1]. The high uncertainty
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in infectious disease epidemiology results also from inter-
dependency among individuals.When prospective studies
or randomized controlled trials are available, they usually
represent selected groups with as little variance as pos-
sible and may not apply to other populations [2]. Such
lack of generalizability may be more problematic for the
recommendations developed by international organiza-
tions. Those guidelines use the best available information
and expert opinion. Nonetheless the yield, eﬀective-
ness and cost of the interventions vary signiﬁcantly due
to heterogeneity of the populations in which they are
implemented [1,3].
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Science-basedmathematical models commonly support
public health decisions [4-7]. Many models were devel-
oped to explain or predict the course of an epidemic for
speciﬁc interventions. However, these models are lim-
ited by the uncertainty of the data and assumptions they
employ [5,7].
Despite severe uncertainty in public health decision-
making, actions must be timely and cost-eﬀective. Analy-
sis of uncertainty is central in responsible decisionmaking
using uncertain data and models.
Information-gap (info-gap) theory [8] was developed for
decision making when knowledge gaps are substantial,
worst cases cannot be reliably identiﬁed, and probabil-
ity distributions are unreliable or unavailable. An info-gap
model is the disparity between what is known and what
needs to be known in order to achieve an acceptable
outcome. The focus is on robustly achieving satisfactory
outcomes, thus making this technique suitable for pub-
lic health policy decision making [9]. Info-gap theory has
been applied in engineering, biological conservation, eco-
nomics, project management, medicine and homeland
security (see http://info-gap.com).
We develop a framework for the practical use of info-gap
theory in public health for controlling infectious diseases.
We focus on tuberculosis (TB) in the context of pandemic
HIV as an example.
Methods
Epidemiological background
TheWorld Health Organization reported 9.4 million inci-
dent TB cases and 1.7 million TB deaths in 2009 and
estimated that only 63% of annual incident TB cases
were detected and reported; of these, 86% were success-
fully treated [10,11]. Given the disease burden, the United
Nations Millennium Development Goals include targets
and indicators related to TB control. The targets include
decreasing TB incidence by 2015, halving TB prevalence
and mortality by 2015 (compared with 1990), and diag-
nosing 70% of new smear-positive cases and curing 85%
of these cases by 2015. However, despite current eﬀorts,
many countries will not achieve these targets [10-14].
The HIV-AIDS pandemic is the major worldwide chal-
lenge to TB control [11,13,15,16]. HIV creates a situation
of serious uncertainty for public health interventions
based on pre-HIV era models [10,11,13]. This is reﬂected
in population distribution, spread, control, and recur-
rence. Latently and actively infected individuals con-
tribute diﬀerently to spread of disease. It is necessary to
consider infectivity, rapidity of progression, re-infection,
individuals with higher susceptibility for infection and
reinfection resulting from HIV coinfection, etc. in order
to produce reﬁned models of diagnosis and treatment.
Many diﬀerent epidemiological models have been
used to evaluate treatment strategies. Deterministic
compartment models are the most common, and we use
a slightly modiﬁed version of the widely used Murray-
Salomon model [17-19] to describe the evolution of
TB/HIV epidemics under various scenarios. The details
of the model appear in Appendix “The Murray-Salomon
model” section.
Info-gap theory
The robustness function is the basic decision-support tool
in an info-gap analysis. If our dynamic model were accu-
rate we could evaluate any proposed intervention in terms
of the outcome of that intervention that is predicted by the
model. An intervention with low predicted TB prevalence
is preferred over an intervention with higher predicted
prevalence.
The problem is great model uncertainty. This means
that predicted outcomes are unreliable and it is unrealis-
tic to prioritize interventions in terms of their predicted
outcomes. Using the model to ﬁnd the intervention whose
predicted outcome is best, is not suited to planning with
highly uncertain models.
Model-based predictions are useful, but when decid-
ing which public health intervention to implement, we
should also ask: how wrong could the model be, and an
acceptable outcome is still guaranteed? For any speci-
ﬁed intervention we ask: what is the largest error in the
model, up to which all realizations of the model would
yield acceptable outcomes? Equivalently, what outcomes
can reliably be anticipated from this intervention, given
the unknown disparity between the model and reality?
Answers to these questions lie in the robustness func-
tion, speciﬁed in Appendix “Deﬁnition of robustness”
section. The robustness is dimensionless, and equals the
greatest fractional error in the model parameters that is
consistent with a speciﬁed outcome requirement. We use
the robustness function to prioritize the interventions in
terms of their robustness against uncertainty for achieving
the required outcome.
Knight [20] recognized that probability distributions
are sometimes unknown and that severe uncertainty may
be non-probabilistic. Wald [21], Ben-Tal and Nemirovski
[22] and others developed tools for robustly managing
non-probabilistic uncertainty by minimizing the worst
outcome on a set of possibilities. Info-gap theory is non-
probabilistic and handles situations where worst cases are
unknown.
We summarize here the main attributes of the info-gap
robustness function: a plot of robustness-to-uncertainty
versus required performance. This is the basic info-gap
tool for prioritizing available options.
Robustness trades oﬀ against performance [23,24]
More demanding performance requirements are
less robust against uncertainty than less demanding
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requirements. This trade oﬀ is quantiﬁed and expressed
graphically by the monotonic robustness curve.
Model predictions have zero robustness against uncertainty
[25]
When models are highly uncertain, it is unrealistic to pri-
oritize one’s options based on predicted outcomes of those
options, because those predictions have no robustness to
errors in the underlying models. Options must be eval-
uated in terms of the level of performance that can be
reliably achieved; this is expressed by robustness.
Combining the trade oﬀ and zeroing properties yields
realistic prioritization of options.
Prioritization of options depends on performance
requirements
Prioritization of options may change as requirements
change. This is called “preference reversal” and is
expressed by the intersection of the robustness curves of
diﬀerent options. Preference reversal provides insight to
anomalous behavior such as the Ellsberg and Allais para-
doxes in human decision making [8], the equity premium
puzzle in economics [8], and animal foraging [26]. We will
show that preference reversal occurs when selecting pub-
lic health interventions because priorities are time- and
context-dependent.
Info-gapmodels of uncertainty are non-probabilistic
Info-gap robustness analysis is implementable even
when probability distributions are unknown, and thus
is suited to severe uncertainty. In contrast, Monte
Carlo simulation, Bayesian analysis, or probabilistic risk
assessment require knowledge of probabilities. Other
non-probabilistic tools include interval analysis, fuzzy set
theory [27], possibility theory [28] and Robust Decision
Making (RDM). A comparison of info-gap and RDM has
recently been published [29].
Info-gap is operationally distinct from themin-max or
worst-case decision strategy [9]
Info-gap robustness does not require knowledge of a worst
case. When even typical scenarios are poorly character-
ized, it is usually impractical to characterize worst cases,
which is required by the min-max strategy. Info-gap the-
ory does require specifying acceptable outcomes. Thus it
is well suited to policy making, because preferences on
outcomes are the driving force.
Info-gap robustnessmay proxy for the probability of
satisfying the performance requirement [8,30,31]
A more robust option is often more likely to achieve
the required outcome. By prioritizing the options using
info-gap robustness, one maximizes the probability of sat-
isfying the requirement, without knowing probability dis-
tributions. The proxy property is central to understanding
survival in economic [8], biological [26] and other com-
petitive environments [31].
Info-gap implementation
Info-gap methodology requires three main elements: a
system model, a performance measure, and a model of
uncertainty. The system model is a mathematical repre-
sentation of a system and its inﬂuence on the variables
of interest, for which management aspirations (perfor-
mance criteria) are set. A performance measure assesses
value or utility of outcomes. The model of uncertainty is
a non-probabilistic representation of the degree to which
the value of parameters, the form of a function, or the
structure of a model may deviate from nominal estimates.
The system model in our example is summarized in two
functions. C(t) is the variation over time of the total num-
ber of TB cases, untreated and treated, HIV-positive and
HIV-negative, as a fraction of the initial population. R(t) is
the total number of relapses, fast and slow, HIV-positive
and HIV-negative, as a fraction of the initial population.
(See eqs.(23) and (24) in Appendix “The Murray-Salomon
model” section.)
The public health practitioner wishes to control the
total number of TB cases: the fewer the better. How-
ever, trying tominimize this prevalence depends onmodel
predictions that are highly uncertain. The performance
requirement is to keep the total fraction of TB cases at
a speciﬁed time, tm, below a critical value, Cm, eq.(25) in
Appendix “Performance requirements” section.
Grassly et al [32] note, in discussing epidemiology of
HIV/AIDS, that “not all sources of error are amenable to
statistical analysis” (p.i37), due to biased, inaccurate or
unavailable data. The basic idea of info-gap model uncer-
tainty is that we do not know howwrong our estimates are,
we have no reliable knowledge of worst cases, and we do
not know probability distributions for the estimates. The
info-gap model uncertainty model is a non-probabilistic
quantiﬁcation of uncertainties.
A dominant uncertainty in TB dynamics with HIV
prevalence is in model parameter values, though HIV
causes signiﬁcant uncertainties in model structure. Struc-
tural uncertainty refers to missing terms in the equations,
missing equations, or unknown nonlinearities. Structural
uncertainty is dealt withmuch less frequently than param-
eter uncertainty because of technical challenges.We focus
on parameter uncertainty in this paper because of its
importance and to facilitate the presentation of this ﬁrst
application of info-gap theory to public health.
We use info-gap theory [8] to model and manage uncer-
tainties in the following parameters: slow and fast relapse
rates for HIV positives and negatives, TB infection rates
for HIV positives and negatives, and the HIV infection
rate. Much literature suggests these parameters for their
impact on the course of epidemics and the diﬃculty
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in measuring them [10,11,16,33-36]. Other uncertain-
ties could also be investigated, depending on the pur-
pose of the analysis. We use estimated values for each
uncertain parameter, and estimated errors typically cho-
sen as half of an interval estimate of the parameter. The
info-gap model of uncertainty is speciﬁed in Appendix
“Uncertainty” section.
We aim to achieve the performance requirement by
judicious choice of control variables, deﬁned in Appendix
“Control variables” section. Eligible control variables are
any coeﬃcients of the dynamic model that can be inﬂu-
enced by public health or related medical intervention.
We use the diagnosis rate, cure rate, relapse rate, and HIV
infection rate. We deﬁne an intervention in terms of the
values of these variables [15,34,37-40].
Results: robustness and policy evaluation
We use the info-gap robustness function to evaluate
alternative interventions aimed at controlling the rela-
tive TB prevalence, C(t), at a speciﬁed target time, tm,
in the future. An intervention is speciﬁed by the values
of the control variables. The evaluation leads to realis-
tic assessment of outcomes and preferences among the
interventions.
Interpreting robustness curves: trade oﬀ and zeroing
All info-gap robustness curves have two properties,
mentioned earlier: trade oﬀ between performance and
robustness, and zeroing of the robustness curve. These
properties are central in using robustness curves to evalu-
ate public health policy.
The coeﬃcients of the epidemiological models are spec-
iﬁed in Tables 1 and 2. Thoughout our examples, the initial
conditions correspond to low TB and low HIV prevalence
(the ﬁrst data-column of Table 3) unless speciﬁed other-
wise. The control variables speciﬁed in Appendix “Control
variables” section are themselves model parameters. The
robustness curve in Figure 1 is evaluated for the nominal
values of the control variables speciﬁed in Tables 1 and 2.
This set of control variables is the “baseline intervention”.
The uncertain variables speciﬁed in Appendix “Uncer-
tainty” section are also model parameters. Their nominal
values and uncertainty estimates are speciﬁed in Table 4.
These nominal values are the same as appear in Tables 1
and 2 for these variables. The total case load is evaluated
at time tm = 10 years after initiation unless indicated
otherwise.
Figures 2 and 3 show the temporal evolution of the rel-
ative prevalence of TB cases, C(t), and relative relapses,
R(t), based on the nominal estimates of the model param-
eters, with moderately low initial TB and HIV prevalence.
C(t) and R(t) are fractions of the initial total population
size. Figure 2 shows that the total number of TB cases
starts at about 4.2% of the initial population and decays
to about 3% in the ﬁrst 1.5 years, thereafter decaying
more slowly, reaching 2.1% of the initial population size
after 10 years. The relapse population starts very small,
rises rapidly in the ﬁrst year and thereafter decays grad-
ually. The reduction in the rate of decrease of the TB
cases after 1.5 years, Figure 2, results from the inﬂux
of relapses which have built up since initiation of the
intervention.
Trade oﬀ
Key to understanding the trade oﬀ expressed by the
robustness curve is the concept of satisﬁcing. In contrast
to optimizing, satisﬁcing asks for an outcome that meets
minimal needs but may not be the best imaginable. The
satisﬁcing strategy is not merely “accepting second best.”
Satisﬁcing is aspirational, setting a goal just like opti-
mization, but also requiring robustness to uncertainty.
The satisﬁcing strategy induces a trade oﬀ between the
aspiration for good outcome and the robustness against
uncertainty in attaining that outcome.
The robustness curve in Figure 1 is based on satisﬁcing
the relative TB prevalence: requiring that the prevalence
not exceed the critical value, Cm. Figure 1 shows the
robustness vs. the critical prevalence. The positive slope
of the robustness curve in Figure 1 expresses the trade
oﬀ between robustness and performance: large robust-
ness entails large prevalence at the speciﬁed target time
(10 years). Equivalently, requiring low relative prevalence
entails low robustness to uncertainty in the epidemiolog-
ical model. The robustness curve quantiﬁes the intuition
that more demanding outcomes (small prevalence) are
more vulnerable to model uncertainty (small robustness).
We can interpret the numerical values along the robust-
ness curve as follows. The prevalence, C(t), and its critical
value, Cm, are normalized to the initial population size.
For instance, Cm = 0.025 means that the prevalence at
time tm must not exceed 2.5% of the initial population
size. The robustness corresponding to this value of Cm, is
0.1 as seen in Figure 1. This means that the performance
requirement is guaranteed if the uncertain model param-
eters vary from their nominal values by no more than
10% of their error estimates. (The model parameters are
constrained to be positive since they are ﬁrst-order rate
constants.)
The public health practitioner may feel that robust-
ness to 10% uncertainty in the model parameters is rather
small, given the substantial uncertainty in the epidemio-
logical dynamics of TB with HIV prevalence. If we want
robustness to, say, 25% uncertainty in the model parame-
ters we must accept a larger ﬁnal case load, namely, Cm =
0.033 as seen in Figure 1. Greater robustness is obtained
only by accepting poorer outcome; this is an irrevocable
trade oﬀ that is quantiﬁed by the robustness curve.
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Table 1 Model parameters in theMurray-Salomon basic model
Symbol Deﬁnition HIV neg HIV pos
Birth rate g births/year/person 0.03c 0c,h
N population size 0.821i 0.179i
T births per year = birth rate×Nc
λ g infection rate 1.81 × 10−3 m 2.96 × 10−3 m
Kk # respiratory contacts with infected/person/year
Lk probability that respir. contact with infectious source leads to infection
KL 5–15a
Yk # infectious cases in population
μ g non-TB death rate 0.009c 0.05c
p proportion of new infections entering slow breakdown 0.9 (0.85–0.95)a 0.4 (0.3–0.5a)
βF
g fast breakdown rate 2c 3
βS
g slow breakdown rate 0.001 (5–15 × 10−4 a) 0.075 (0.05–0.10a)
χ g rate of application of INH to infected individuals 0.75 ()
ν protection from superinfection conferred by primary infection 0.75 (0.5–1a)
w short-term INH eﬀectiveness 0.7
h long-term INH eﬀectiveness 0.7
di,j proportion of pre-diagnosed cases in clinical category i entering diagnosis category j
d1,1 0.45 (0.4–0.5)j 0.35 (0.3–0.4)j , e
d2,1 0.55 (0.5–0.6) 0.65 (0.6–0.7) e
d3,1 e
di,2 di,2 = 1 − di,1 f
si proportion of new cases in clinical category i
s1, s2 proportion of new cases in clinical category i 0.45 (0.4–0.5a)
s3 proportion of new cases in clinical category i s3 = 1 − s1 − s2 d
δj g diagnosis rate for category j 0.6  0.6 
σ g smear conversion rate 0.03 c
Model parameters in the Murray-Salomon basic model, Table Two, p.42, in ref. [18], except for K, L, Y and Nwhich are deﬁned in footnote 2 on p.21 of [18]. Where a
value is speciﬁed only for HIV-negative, the same value is used for HIV-positive.
aFootnote 8, p.24, [18].
bFootnote e, Table A5, p.63, [18].
cTable A5, p.63, [18].
dFootnote c, Table A5, p.63, [18].
eFootnote ‡, Table A5, p.63, and Figure A5, p.57 [18].
fFootnote b, Table A5, p.63,[18].
gRate: per person per year. In Botswana the average is 477 cases per year per 100,000 people. 62% of them are HIV infected.
hDepends on HIV prevalence. In areas with HIV and without preventive treatment, 25% of babies born from HIV mothers are infected.
iIn Botswana.
j[Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country.
WHO Global Surveillance and Monitoring Project. JAMA. 1999 Aug 18;282(7):677–86.].
kNot needed since λ is a primary datum.
Decision variable.
mCan also be treated as a decision variable.
Zeroing
We note that the robustness curve in Figure 1 reaches the
horizontal axis at the value Cm = 0.021. This means that
requiring the prevalence not to exceed 2.1% of the initial
population has no robustness against model uncertainty.
The value of Cm at which the robustness becomes zero
is precisely the nominal prediction of the prevalence at
time tm as seen by the right end-point in Figure 2. That
is, the value of C(tm), evaluated with the best estimates of
the model parameters, equals 0.021. The horizontal inter-
cept in Figure 1 is an example of the property of zeroing
that holds for all info-gap robustness curves: The outcome
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Table 2 Model parameters in theMurray-Salomon basic model
Symbol Deﬁnition HIV neg HIV pos
εU
f spontaneous cure rate for untreated cases 0.2 (0.14–0.25)g
μiU














gi,2 gi,2 = 1 − gi,1 e
εkT

























rU proportion of spontaneously recovered cases entering the slow relapse category 0.009c






f fast relapse rate 2c 3
ρS
f slow relapse rate 0.001 (5–15 × 10−4 a)
γ f rate of HIV infection 0.075 (0.011–0.95)h
Model parameters in the Murray-Salomon basic model, Table Two, p.42, in ref. [18], except for K, L, Y and Nwhich are deﬁned in footnote 2 on p.21 of [18]. Where a
value is speciﬁed only for HIV-negative, the same value is used for HIV-positive.
aFootnote 8, p.24, [18].
bFootnote e, Table A5, p.63, [18].
cTable A5, p.63, [18].
dFootnote ‡, Table A5, p.63, and Figure A4, p.56 [18].
eFootnote d, Table A5, p.63, [18].
fRate: per person per year.
g[33,34]. Other estimate: 0.05–0.15a .
h[1].
predicted by the model, when adopted as the performance
requirement, has no robustness against uncertainty in
the model.
It is not surprising that the predicted outcome is
extremely vulnerable to error in themodel upon which the
prediction is based. However, the zero-robustness of pre-
dicted outcomes has an important implication for policy
selection.
The robustness curve in Figure 1 is for a particular
choice of values of the control variables: the baseline
intervention. The zeroing property—no robustness of the
predicted outcome of these control values—implies that
we should not assess these control values in terms of
their predicted outcome. The predicted prevalence of
0.021 at time tm = 10 years does not reliably reﬂect
the performance of these control variables. Due to the
trade oﬀ property, only larger prevalence can reliably be
expected to result from this choice of the control vari-
ables. Predicted outcomes are not reliable for prioritizing
the interventions.
Equivalent interventions
Diﬀerent combinations of interventions can yield essen-
tially equivalent results, as in Figure 4. The baseline
intervention (solid), is characterized by low diagnosis rate
and high relapse rate. The other intervention (dash) has
higher diagnosis rate and lower relapse rate as speciﬁed in
Table 5. (Interventions are speciﬁed by the values of con-
trol variables presented in Table 5). The robustness curves
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Table 3 Initial conditions
Symbol Low TB Prevalence Medium TB Prev. High TB Prev.
Low Med High Low Med High Low Med High
HIV HIV HIV HIV HIV HIV HIV HIV HIV
1 U 0.9 0.8 0.6 0.8 0.650 0.500 0.6 0.5 0.4
2 IF 0.0075 0.015 0.03 0.011 0.018 0.028 0.03 0.0375 0.045
3 IS 0.03 0.06 0.12 0.05 0.088 0.125 0.12 0.15 0.18
4 SF 0.003 0.006 0.012 0.01 0.018 0.025 0.012 0.015 0.018
5 HS 0.009 0.018 0.036 0.02 0.035 0.050 0.036 0.045 0.054
Ci,jU
6 (i, j) = (1, 1) 0.005 0.01 0.02 0.008 0.014 0.020 0.02 0.025 0.03
7 (i, j) = (2, 1) 0.002 0.004 0.008 0.003 0.005 0.008 0.008 0.01 0.012
8 (i, j) = (3, 1) 0.002 0.004 0.008 0.003 0.005 0.008 0.008 0.01 0.012
9 (i, j) = (1, 2) 0.002 0.004 0.008 0.003 0.005 0.008 0.008 0.01 0.012
10 (i, j) = (2, 2) 0.001 0.002 0.004 0.002 0.004 0.005 0.004 0.005 0.006
11 (i, j) = (3, 2) 0.001 0.002 0.004 0.002 0.004 0.005 0.004 0.005 0.006
Ci,kT
12 (i, k) = (1, 1) 0.01 0.02 0.04 0.02 0.035 0.050 0.04 0.05 0.06
13 (i, k) = (2, 1) 0.005 0.01 0.02 0.01 0.018 0.025 0.02 0.025 0.03
14 (i, k) = (3, 1) 0.005 0.01 0.02 0.01 0.018 0.025 0.02 0.025 0.03
15 (i, k) = (1, 2) 0.005 0.01 0.02 0.02 0.035 0.050 0.02 0.025 0.03
16 (i, k) = (2, 2) 0.002 0.004 0.008 0.005 0.009 0.013 0.008 0.01 0.012
17 (i, k) = (3, 2) 0.0025 0.005 0.01 0.003 0.005 0.008 0.01 0.0125 0.015
18 RF 0.002 0.004 0.008 0.005 0.009 0.013 0.008 0.01 0.012
19 RS 0.006 0.012 0.024 0.015 0.025 0.038 0.024 0.03 0.036
1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000














Figure 1 Robustness of relative TB prevalence. Run 8.
for these two control strategies, at 10 years, are nearly the
same, suggesting that the public health practitioner may
choose freely between them, perhaps employing addi-
tional criteria such as cost or ease of implementation.
Equivalence may be lost if parameters are changed. For
instance, we will see later (Figure 5) that these interven-
tions evaluated at 10, 20 or 30 years have very diﬀerent
robustness curves.
Table 4 Nominal values and error weights of uncertain
variables
Symbol Nominal value, u˜i Error weight, si
λ 1.81 × 10−3 0.0009
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Figure 2 Relative TB prevalence vs. time. Run 8.
Figure 6 shows a diﬀerent aspect of the equivalence
of interventions. The ﬁgure shows robustness curves for
two strategies speciﬁed in Table 5. Both strategies aim to
control the relative prevalence of TB, but one (solid) is
geared for a 10-year target time, while the other (dash)
considers a 30-year target. The estimated outcomes—
prevalence—are very nearly the same for these two
strategies, each at its respective target time, as shown by
their shared horizontal intercept at Cm = 0.018. These
predictions result from estimated model parameters, so
one might be inclined to conclude that TB prevalence of
0.018 can be achieved at either 10 or 30 years by using the
corresponding intervention.









Figure 3 Relative relapses vs. time. Run 8.














Figure 4 Equivalent robustness for two interventions. Run 8: —,
run 15: – –.
However, the epidemiological model is highly uncertain,
and the robustness curves in Figure 6 of these two strate-
gies are quite diﬀerent. Not surprisingly, the 30-year target
is much less robust to uncertainty. It would be erroneous
to treat these two strategies as outcome-equivalent since
their performances at positive robustness are quite dif-
ferent. Nominal equivalence (equivalence of the predicted
outcome) does not imply robustness equivalence.
Impact of initial TB and HIV prevalence
We now consider higher initial prevalences. The overall
shape of the dynamic response is very similar in each case,
except that the prevalence increases signiﬁcantly as the
initial prevalence increases. As in Figures 2 and 3, in each
scenario the initial TB prevalence decreases rapidly dur-
ing the ﬁrst 2 years, and thereafter decreases more slowly
as the new relapse population—which peaks around the
end of the ﬁrst year—ﬂows back into active cases.
Figure 7 shows robustness curves for a target time 10
years after initiation, for low (solid), medium (dash) and
high (dot-dash) initial prevalence of TB and HIV. The
low-prevalence curve (solid) is the same as Figure 1. The
robustness curves shift dramatically to the right as the
baseline prevalence of TB and HIV increases, indicat-
ing poorer estimated outcome and lower robustness to
uncertainty.
Intervention aggressiveness
Figure 8 shows robustness curves for low initial TB and
HIV prevalence with interventions speciﬁed in Table 5.
The solid curve is the baseline intervention, against which
the other curves entail more aggressive intervention in
either or both the active cases and the relapse population.
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Table 5 Control variables for robustness curves
Run Init tm δj = δj εkT = εkT ρF ρF λ λ γ βF βF
Prev a (yr)
8 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
9 1 10 (0.65, 0.65) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
10 1 10 (0.65, 0.65) (0.88, 0.55) 2 3 0.00181 0.00296 0.075 2 3
11 1 10 (0.65, 0.65) (0.88, 0.55) 1.5 2.25 0.00181 0.00296 0.075 2 3
12 1 10 (0.65, 0.65) (0.88, 0.55) 1 1.5 0.00181 0.00296 0.075 2 3
15 1 10 (0.85, 0.85) (0.8, 0.5) 1.2 2 0.00181 0.00296 0.075 2 3
19 5 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
21 5 10 (0.65, 0.65) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
22 5 10 (0.65, 0.65) (0.88, 0.55) 2 3 0.00181 0.00296 0.075 2 3
23 5 10 (0.65, 0.65) (0.88, 0.55) 1 1.5 0.00181 0.00296 0.075 2 3
20 9 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
24 9 10 (0.65, 0.65) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
25 9 10 (0.65, 0.65) (0.88, 0.55) 2 3 0.00181 0.00296 0.075 2 3
26 9 10 (0.65, 0.65) (0.88, 0.55) 1 1.5 0.00181 0.00296 0.075 2 3
27 1 20 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
28 1 30 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
29 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.0375 2 3
30 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.05 2 3
31 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.06 2 3
32 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.0009 0.00148 0.075 2 3
33 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.0003 0.0005 0.075 2 3
38 1 30 (0.85, 0.85) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 2 3
39 1 10 (0.6, 0.6) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 1 1.5
41 1 10 (0.65, 0.65) (0.8, 0.5) 2 3 0.00181 0.00296 0.075 1 1.5
aData-column in Table 3.
The progression from solid to dash to dot-dash in
Figure 8 represents increasingly aggressive intervention
in the active TB case population. We see that increasing
aggressiveness, in this speciﬁc parameter conﬁguration,
results in increasing prevalence and decreasing robust-
ness to model error at the target time. The explanation
is that aggressive treatment of active cases enlarges the
relapse population which ﬂows back into the active case
population.
The top curve in Figure 8 modiﬁes the most aggressive
case (dot-dash) by also including more aggressive inter-
vention in the TB relapse population. This reduction in
relapse reduces the predicted prevalence after 10 years,
and increases the robustness to uncertainty.
Diﬀerent target times
Most of the results discussed so far evaluated the robust-
ness for a target time 10 years after initiation. We now
consider the implications of diﬀerent target times.
Figure 5 shows robustness curves at target times, tm,
of 10, 20 and 30 years (solid, dash, dot-dash respec-
tively). The initial prevalences of TB and HIV are low. The
interventions are all at the baseline.
The predicted prevalence decreases as the target time
increases, as shown by the horizontal intercepts in
Figure 5. The baseline intervention is predicted to reduce
the prevalence, (in units of initial population size), as
the time horizon increases. However, the zeroing prop-
erty means that these predictions have no robustness to
uncertainty in the model used for prediction. Only higher
prevalence has positive robustness.
From Figure 5 we see that, for critical TB prevalence Cm
less than 3%, the 30-year TB prevalence is more robust
than the 20-year prevalence which is more robust than
the 10 year prevalence. For instance, at critical TB preva-
lence of Cm = 0.02, the robustnesses for 10, 20 and 30
year horizons are 0, 0.08 and 0.12, respectively. This inter-
vention has no robustness to uncertainty when requiring a


















Figure 5 Robustness curves at 10, 20 and 30 years. Run 8: —, run
27: – –, run 28: ·–.
2% prevalence after 10 years; in fact, the estimated preva-
lence at 10 years is greater than 2%. The prevalence at 20
years will be no worse than 2% provided that the model
coeﬃcients err by no more than 8%, and at 30 years the
robustness to error is 12%.
The practitioner may feel that even 12% robustness
against model-coeﬃcient error is rather small, given the
severe uncertainty of TB epidemiology in the context of
epidemic HIV. This means that, even at a 30-year hori-
zon, this intervention cannot reliably achieve a relative
prevalence as low as 2%.
















Figure 6 Nominal equivalence of two interventions. Run12: —,
run 38: – –.















Figure 7 Robustness curves for low, medium and high initial TB
and HIV prevalence. Run 8: —, run 19: – – run 20: ·–.
Suppose we are willing to aim at a ﬁnal TB prevalence of
3.7%. We see from Figure 5 that now the 10-year horizon
is more robust than 20 years which is more robust than 30
years. The robustnesses are now 30%, 24% and 22% for 10,
20 and 30 years. The robustness curves have intersected
one another and the robustness rankings are reversed. As
the target time decreases, the predicted outcome becomes
worse (horizontal intercept moves right) but the cost of
robustness improves. This causes the robustness curves to
cross one another. More intuitively, we can say that pre-















Figure 8 Robustness with varying aggressiveness. Run 8: —, run
9: – –, run 10:·–, run 12: · · ·.
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horizon than for long times. But since a long time is
required to overcome the relapse eﬀect, we observe the
intersection of the robustness curves and the consequent
reversal of their robust dominance.
Results like Figure 5 have important policy implications
for TB control over long time periods. The policy maker
may be tempted to choose one option that is predicted to
yield better short term results. However, that choicemight
be wrong when one opts to satisﬁce the outcome with
robustness to uncertainty. Predictions of mathematical
models (horizontal intercepts) are not suﬃciently reliable
for comparing and prioritizing interventions; the cost of
robustness (slope) must also be considered. In the exam-
ple in Figure 5 one might conclude that prevalence less
than 3% is not achievable at any target time, that 3.7%
is feasible at 10-years but not beyond, and that other
interventions are needed for longer-term outcomes.
Impact of HIV mortality
Figure 9 shows 10-year robustness curves for various HIV
infection rates, with low initial TB and HIV prevalence,
as speciﬁed in Table 5. The HIV infection rate decreases
in the progression from solid, dash, dot-dash to dot-dot.
As the HIV infection rate decreases, the estimated 10-year
TB prevalence increases and the robustness decreases.
The explanation lies in the high mortality rate of the
HIV population. As the HIV infection rate decreases, the
size of the relapse population decays more slowly, allow-
ing greater ﬂow back into the active TB case population.
Interventions that decrease HIV infection rates or restore
immunity to HIV patients, will counter-intuitively tend to














Figure 9 Robustness for various HIV infection rates. Run 8: —, run
31: – –, run 30: ·–, run 29: · · ·.
increase TB prevalence unless compensatingmeasures are
taken. Signiﬁcantly, the cost of robustness (slope of the
robustness curve) does not change as a result of decreased
HIV infection rate. Reducing HIV infection rate shifts
the robustness curve to the right, with almost no change
in slope.
Conclusion
We demonstrated a generic info-gap framework for
managing model uncertainty in public health decision
making. By applying it to a mathematical model of
TB/HIV epidemics, we illustrated speciﬁc recommenda-
tions for interventions in the control of TB with HIV in
various settings.
The complicated multi-dimensional epidemiological
dynamics are dominated by the ﬂow back and forth
between the actively and latently infected TB populations
and the diﬀerent rates of progression of diﬀerent subpopu-
lations between these compartments. Counter-intuitively,
the total TB case load even decades after initiation can
increase as a result of increased diagnosis and cure rates,
and it can increase as the control of HIV becomes more
aggressive. These ﬁndings highlight the critical impor-
tance of modeling in the assessment and planning of
public health intervention. Model predictions are often
used to choose interventions. However, model predic-
tions must be interpreted in light of model uncertain-
ties. Predicted outcomes have zero robustness to model
error. Only worse-than-predicted outcomes (higher rel-
ative prevalence) have positive robustness against model
error. This means that predicted outcomes are not reliable
for prioritizing the interventions. The trade oﬀ between
robustness and outcome is quantiﬁed by the info-gap
model analysis and is a critical component of the decision-
making process.
We explore the performance of interventions that alter
the rate constants of diagnosis, cure, relapse and HIV
infection. Some interventions have quite similar predicted
outcomes and robustness curves. This enables the policy
maker to choose between these interventions based on
additional criteria, such as ease or cost of implementation.
It is not true, however, that interventions with the same
estimated outcomes necessarily have the same robustness
against model error.
We demonstrate the policy implications of initial TB
and HIV prevalence, of HIV mortality, of degree of treat-
ment aggressiveness, and of the target time at which
outcomes are evaluated. Public health policies are evalu-
ated in terms of conﬁdence—expressed as robustness to
modeling error—in achieving speciﬁed TB prevalence at
the target time. Predicted outcomes have zero robustness
and thus are not reliable for evaluating and comparing
interventions. Instead, interventions must be prioritized
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in terms of their capacity for achieving speciﬁed out-
comes, with robustness to uncertainty. Failure to quantify
the uncertainty inherent in public health interventions
leads to disappointment from unrealized expectations,
and failed policy. Where a public health model under-
lies guidelines, info-gap decision theory provides valu-




The Murray-Salomon (M-S) model [17,18] is a set of
coupled diﬀerential equations that describe the time evo-
lution of TB. A modiﬁcation deals with TB infecteds in a
population containing HIV smear-positive individuals. In
section “The basic Murray-Salomon model: No HIV” we
deﬁne the basic non-HIV model. In section “The HIV-Ex-
tended model” we present the M-S extension to include
an HIV sub-population. The state variables are deﬁned in
Table 6 and the parameters are deﬁned in Table 1.
The basic Murray-Salomonmodel: No HIV
The basic M-S model is the following 19 diﬀerential
equations (eqs.(6) and (7) occur in 6 diﬀerent forms each)
appearing on pp.19–20 of Murray and Salomon [18]:
dU
dt = T − λU − μU (1)
dIF
dt = (1 − p)λU − βFIF − wχ IF − μIF (2)
dIS





dt =χ(wIF + wSF + IS) − (1 − p)λ(1 − ν)HS
− (1 − h)βSHS − μHS
(5)
Table 6 State variables—sizes of sub-populations—in theMurray-Salomon basic model, Table One, p.41, in ref. [18]
Index Symbol Deﬁnition Initial valuea
HIV Neg HIV pos Ref.
1 U Uninfected 0.9b 0.2c [10]
2 IF Infected subject to fast breakdown 0.05–0.1 0.1 [33,34]
3 IS Infected subject to slow breakdown 0.1 0.1 [33,34]]
4 SF Superinfected subject to fast breakdown 0
5 HS INH recipient subject to slow breakdown 0.01 0.01–0.03
6–11 Ci,jU Untreated cases, of 6 types: 0
i = 1: smear-positive pulmonary
i = 2: smear-negative pulmonary
i = 3: extra-pulmonary
j = 1: fast diagnosis category
j = 2: slow diagnosis category
i = 2 if i = 1 (eqs.(6) and (7))
i = 1 if i = 2 (eqs.(6) and (7))
i = 0 if i = 3 (eqs.(6) and (7))
12–17 Ci,kT Treated cases, of 6 types: 0
i as above
k = 1: good treatment category
k = 2: bad treatment category
18 RF Recovered cases subject to fast relapse 0.4 (0.28–0.52) [33,34]
19 RS Recovered cases subject to slow relapse 0.050 (0.035–0.065) [33,34]
The deﬁnition of superscript i is in [18] on p.20.
aAs fraction of total population at start of simulation.
bLow prevalence.
cHigh prevalence.
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dCi,jU
dt ={βF (IF + SF ) + βS[ IS + (1 − h)HS]
+ρSRS + ρFRF } di,jsi
− δjCi,jU ± σCi
 ,j
U − εUCi,jU − (μ + μiU)Ci,jU , (6)







T − εkTCi,kT − (μ + μi,kT )Ci,kT , (7)
for i = 1, 2, 3 and k = 1, 2
dRF




























− ρSRS − (1 − p)λ(1 − ν)RS − μRS (9)
The term ‘±σ ’ appears in eqs.(6) and (7). M-S write:a
It should be noted in the equations for Ci,jU and C
i,j
T
that the smear rate σ is multiplied by the number of
individuals in the respective category i, where i = 2
(smear-negative) for i = 1 (smear-positive) and vice
versa, and i = ∅ for i = 3 (extra-pulmonary). The
term including σ is added for i = 1, subtracted for
i = 2, and equal to 0 for i = 3. The result of this
formulation is that smear-negative patients convert
to smear-positive at a rate of σ .
However, the ‘vice versa’ is a mistake. The correct




dt = · · · + σC
2,j
U + · · · (10)
dC2,jU
dt = · · · − σC
2,j
U + · · · (11)
dC3,jU
dt = · · · + 0C
i,j
U + · · · (12)
Eq.(10) states that smear-negative individuals join the
smear-positive population at rate σ . Eq.(11) states that
smear-negative individuals leave the smear negative pop-
ulation at rate σ . That way all individuals are accounted
for.
The instantaneous rate of infection, λ in eq.(1), is
deﬁned by Murray and Salomon [18], p.21, as:
λ = KLYN (13)
The HIV-Extendedmodel
Introduction
We will now formulate the extended dynamic model to
include a diﬀerentiation between HIV-positive and HIV-
negative populations. M-S do this also, and state [18], p.4
that they use “two sub-models—one for the HIV sero-
negative population, and one for the HIV sero-positive
population. Each sub-model follows the structure” which
is presented here as eqs.(1)–(9). They write that
Individuals move from each category in the
HIV-negative sub-model to the corresponding
category in the HIV-positive sub-model at the HIV
infection rate, which varies over time. Because the
eﬀects of HIV on immune function are not marked
with respect to tuberculosis until the CD4 count has
dropped below 500, we actually move individuals
from the HIV-negative to the HIV-positive
sub-model after they have been infected with HIV for
3 years. The two sub-models are also linked through
the annual risk of infection, as HIV-negative
tuberculosis cases can infect HIV-positive
individuals, and vice versa [18], pp.4–5
Our model does not delay transfer from the HIV-
negative sub-model.
Sub-models Each of the two sub-populations—HIV-
negative and HIV-positive—is divided into the 19 groups
represented by the state variables in Table 6. Each state
variable has a diﬀerential equation in eqs.(1)–(9).
Let us denote the HIV-negative state variables as before,
and the HIV-positive state variables with the same letters
but with an over-bar. For compactness we represent these
two sets of variables with two vectors:
x =
(




















































The model parameters listed in Tables 1 and 2 take
diﬀerent values for HIV-negative and HIV-positive pop-
ulations (as speciﬁed in the tables). Let us denote the
model parameters as before for the HIV-negative popula-
tion, and use the same symbols with an over-bar for the
HIV-positive population.
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Eqs.(1)–(9) are 1st-order linear inhomogeneous diﬀer-
ential equations. Only eq.(1) has an inhomogeneous term:
T births per year. Let F(t) and F(t) denote the matri-
ces of coeﬃcients (model parameters) in the diﬀerential
equations for HIV-negative andHIV-positive populations,
respectively. Let e1 denote the 19-vector with a 1 in the
ﬁrst element and zeros elsewhere. We can now compactly
denote eqs.(1) as:
dx
dt = F(t)x + e1T (16)
Let γ denote the HIV infection rate, per person per
year. Following M-S, we will move individuals from each
HIV-negative category to the corresponding HIV-positive
category at rate γ . Thus, instead of eq.(16), we have the
following coupled sets of equations:
dx
dt = F(t)x + e1T − γ x (17)
dx
dt = F(t)x + e1T + γ x (18)
The term ‘−γ x’ in eq.(17) removes individuals from the
HIV-negative population at the HIV infection rate, and
the term ‘+γ x’ in eq.(18) introduces them into the HIV-
positive population at the same rate.
M-S introduce further highly structured coupling
between eqs.(17) and (18) through the TB infection rate,
[18], p.23, λ. We do not employ the M-S diﬀerentiation
between the infection rates for HIV-negative and HIV-
positive populations. Instead we simply use λ and λ for the
TB infection rates in the HIV-negative and HIV-positive
populations.
Uncertainty
Many uncertainties accompany the dynamic model. We
concentrate on uncertainty in the values of some of the
model parameters, as this is the dominant impact of HIV
prevalence. We use info-gap theory to model and manage
these uncertainties [8]. Many diﬀerent types of info-gap
models of uncertainty are available. We employ a model
particularly suited to severe lack of information.
The dominant uncertain parameters are:
ρS, ρS, slow relapse rates.
ρF , ρF , fast relapse rates.
λ, λ, TB infection rates.
γ , HIV infection rate.
Let us denote uncertain variables generically as ui, com-
piled in a vector u. This vector is:
u = (ρS, ρF , λ, ρS, ρF , λ, γ ) (19)
For each uncertain parameter, ui, we have an estimated
value, denoted u˜i, and an error term si typically cho-
sen as half of an interval estimate of the parameter. The
error estimate may be derived from a statistical conﬁ-
dence interval, or from a plausible extension of a conﬁ-
dence interval as discussed by Grassly et al [32], or from
other professional judgment. The basic idea of an info-gap
model of uncertainty is that we don’t know howwrong our
estimate is; we have no reliable estimate of a worst case. In
fact, since the typical values are poorly known, worst-case
estimates are even less reliable.
More precisely, the fractional error of the estimate, u˜i,
in units of the error, si, is unknown. That is, this fractional
error is bounded by a number, α, whose value is unknown:∣∣∣∣ui − u˜isi
∣∣∣∣ ≤ α, α ≥ 0 (20)
But this must be further reﬁned to reﬂect the fact
that the uncertain parameters are 1st-order removal-rate
constantsb, which means that they cannot be negative.
Thus we adjoin these constraints to the inequality as:
ui > 0,
∣∣∣∣ui − u˜isi
∣∣∣∣ ≤ α, α ≥ 0 (21)
Finally, we write our info-gap model of uncertainty as a
family of nested sets of uncertain vectors:
U(α) =
{
u : ui > 0,
∣∣∣∣ui − u˜isi
∣∣∣∣ ≤ α, for all i
}
, α ≥ 0
(22)
α is called the ‘horizon of uncertainty’. When α = 0
there is no uncertainty and the set U(0) contains only
the estimated values, u˜. As α increases, the sets U(α)
become more inclusive. These sets are unbounded in the
space on which the parameters are deﬁned. The info-gap
model embodies the information we have—estimates and
errors—without committing to anymeaningful worst case
(other than the limits which are imposed by the deﬁnition
of the variables).
In some situations one may not be able to estimate error
weights, si. In such situations the fractional error in eq.(20)
can be replaced by a fractional error relative to the esti-
mate, |(ui−u˜i)/˜ui|. The info-gapmodel is then formulated
as in eq.(22) with this new fractional error.
Robustness: formulation
Performance requirements
We will consider an aggregated variable for monitoring
the TB status of the population. Our goal is to keep
the value of this variable acceptably small. The variable
we consider is the total number of cases, untreated and
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Ci,jU (t) + Ci,jT (t) + C
i,j
U(t) + Ci,jT (t)
]
(23)
There are other variables that one could consider. For
instance, one could consider the total number of relapses,
fast and slow, HIV-positive andHIV-negative, as a fraction
of the initial population:
R(t) = RF(t) + RS(t) + RF(t) + RS(t) (24)
One could also consider the instantaneous or the average
rates of change of C(t) and R(t).
Returning to the aggregate prevalence, C(t), our goal is
to keep it below a speciﬁed maximum acceptable value at
a speciﬁed target time tm. Thus the performance require-
ment is:
C(tm) ≤ Cm (25)
A relation such as eq.(25) is called a “satisﬁcing” require-
ment, as opposed to an optimization requirement. We do
not aim to minimize the aggregate prevalence, C(tm). Our
goal is to make the TB prevalence adequately small: no
greater than the critical value Cm, as stated in eq.(25).
Note that the satisﬁcing requirement includes optimiza-
tion as a special case. Satisﬁcing and optimizing are the
same when Cm is chosen as the predicted minimal value.
Control variables
We aim to achieve this goal by judicious choice of control
variables that we denote generically as qi, combined in a
vector q. Eligible control variables are any coeﬃcients of
the dynamicmodel that can be inﬂuenced by public health
or related medical intervention. When a control variable
is also an info-gap uncertain variable we will refer to the
estimated value as the control variable. The uncertainty is
then in whether the speciﬁed value—the estimate—will be
realized in practice.We will consider the following control
variables:
δj, δj, diagnosis rates (same for HIV negative and
positive populations).
εkT , εkT , cure rates for treateds (same for HIV negative
and positive populations).
ρ˜F , ρ˜F , estimated fast relapse rates.
λ˜, λ˜, estimated TB infection rates.
γ˜ , estimated HIV infection rate.
βF ,βF , fast breakdown rates.
We deﬁne an intervention in terms of the values of these
variables. None of these control variables corresponds
directly to any of the standard performancemeasures such
as the incidence, prevalence, and death rates associated
with TB. For instance, the coeﬃcients δj and δj, while
called “diagnosis rates”, are in fact 1st-order kinetic rate
coeﬃcients and can meaningfully take any positive value.
These coeﬃcients combine with several other coeﬃcients
to determine the fraction of new untreated cases that
move into the treated category, as seen from eqs.(6) and
(7). In other words, the control variables combine to pro-
duce aggregate eﬀects such as the proportion of new cases
that are diagnosed. One can “calibrate” a set of control
variables in terms of aggregate properties, for instance by
keeping track of how many cases are created (new mem-
bers of CU(t)) and how many are treated (new members
of CT (t)). Unless the population is at steady state (and
the intervention tries to prevent this), the calibration in
terms of the proportion diagnosed depends on the time
after initiation of intervention and on the duration dur-
ing which the accounting is done. We do not calibrate our
model since we focus on a diﬀerent challenging problem:
prioritizing alternative interventions.
Deﬁnition of robustness
An intervention is speciﬁed by specifying the values of the
control variables, q. If our dynamic model were accurate
we could evaluate any proposed intervention in terms of
the outcome of that intervention that is predicted by the
model. An intervention whose predicted outcome entails
low TB prevalence is preferred over an intervention with
larger predicted prevalence.
The problem is that the dynamic model is highly uncer-
tain. This means that it is unrealistic to prioritize inter-
ventions in terms of their predicted outcomes. Since those
predictions are highly uncertain, it is unwise to eval-
uate interventions only in terms of their model-based
predictions.
The model-based predictions are useful, but we also
ask: how wrong could the model be, and the predicted
outcome is still acceptable? That is, for any speciﬁed inter-
vention, q, we ask: what is the largest fractional error in
the uncertain parameters, up to which all realizations of
the model would yield acceptable outcomes? The answer
to that question is the robustness function, which we will
soon specify. We use the robustness function to priori-
tize the interventions in terms of their robustness against
uncertainty for achieving the required outcomes.
The robustness function for the performance require-












We can “read” this relation from left to right as follows.
The robustness, α̂, of intervention q, with performance
requirement Cm, is the maximum horizon of uncertainty,
α, up to which the maximum aggregate prevalence, C(t),
for all realizations of the uncertain coeﬃcients u in the
info-gap model U(α), does not exceed the critical value,
Cm. We are not ameliorating a worst case; the worst
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case is unknown because the horizon of uncertainty, α, is
unbounded. Instead, we are asking how large an uncer-
tainty can be tolerated by the intervention, q. In choosing
the intervention to enhance the robustness, we attempt to
protect against the unbounded uncertainty of the impact
of HIV/AIDS on the TB dynamics.
Endnotes
aFootnote 1 in the full online version, pp. 20–21.
bThis means that these parameters are the coeﬃcients
in equations such as x˙(t) = −ux(t) whose solution is
x(t) = x(0)e−ut . In order for this to be a removal process,
the coeﬃcient umust be positive. It can exceed unity.
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